Exacerbation burden in patients treated as intermittent or mild-persistent asthma using short-acting β2-agonist rescue
Patients treated as intermittent/mild-persistent asthma rely on SABA and experience exacerbations. Shifting from SABA only to an anti-inflammatory rescue therapy could decrease morbidity.
Authors
- Njira Lucia Lugogo (ORCID: https://orcid.org/0000-0002-0235-7105)
- Ileen Gilbert (ORCID: https://orcid.org/0000-0003-3529-0186)
- Joseph Tkacz (ORCID: https://orcid.org/0000-0003-2369-356X)
- Miguel J. Lanz (ORCID: https://orcid.org/0000-0002-2868-5596)
- Hitesh Gandhi
Institutions
- IBM (United States) (US)
- University of Michigan (US)
- Miami Children's Hospital (US)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Annals of Allergy Asthma & Immunology
- Published
- 2025-02-24
- DOI
- https://doi.org/10.1016/j.anai.2025.02.009
- Citations
- 2
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.33